Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REGN7999 in Non-Transfusion Dependent Beta-Thalassemia
NCT06421636Phase 2Active, not recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Sep 2024
- Primary completion
- Dec 2026
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 9
01
Overview
A Phase 2 trial of REGN7999 in beta thalassemia, sponsored by Regeneron Pharmaceuticals. Started Sep 2024; status: active, not recruiting.
02
Drugs
REGN7999
03
Conditions
beta thalassemia
Beyond the preview
Go deeper on NCT06421636.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06421636.